We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 22, 2021

Risk of Hospitalisation for HF, Kidney Disease, and Death With SGLT2 vs DPP-4 Inhibitors in T2D Regardless of Prior CV or Kidney Disease

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Lower Risk of Hospitalisation for Heart Failure, Kidney Disease and Death With Sodium Glucose Co-Transporter-2 Compared to Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Regardless of Prior Cardiovascular or Kidney Disease: A Retrospective Cohort Study in UK Primary Care
Diabetes Obes Metab 2021 May 11;[EPub Ahead of Print], I Idris, R Zhang, JB Mamza, M Ford, T Morris, A Banerjee, K Khunti, J Tulip Mark Greener

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading